At Finch, discovery and product design begins with proof-of-concept data in humans. We begin in the clinic rather than the lab, using interventional studies to understand how the microbiome drives health outcomes. By using machine learning to analyze clinical data and derive relevant strains, Finch is able to identify meaningful microbial signatures. Rather than relying on in-vitro screening of a library of isolates or looking only at associations between health and the microbiome, this Human First Discovery platform allows us to target the microbes that actually cause dysbiosis and disease.

Finch is rapidly deploying its Human-First Discovery platform to a broad range of diseases linked to dysbiosis of the gut microbiome. We are systematically exploring the most promising diseases by generating and analyzing interventional data to empirically determine whether microbial interventions have a meaningful clinical impact. We are deploying our machine learning platform against these datasets to evaluate whether a Rationally-Selected Microbiota therapy is likely to be efficacious, or whether a Full-Spectrum Microbiota therapy is more promising. Finch is currently involved in 36 clinical trials aimed at addressing important unmet medical needs.